Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy
Glaukos reports positive Phase 4 results for its iDose TR therapy, demonstrating superior efficacy over standalone cataract surgery.
Stocks · News reference
BTIG Maintains Buy on Glaukos, Raises Price Target to $205
BTIG analyst Ryan Zimmerman maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target from $202 to $205.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Glaukos Announces Topline Results From Its Phase 4 Trial Evaluating iDose TR With Cataract Surgery In Patients With Open-Angle Glaucoma Or Ocular Hypertension; Study Met Primary Efficacy Endpoint, Demonstrating Statistically Significant Superiority And Clinically Meaningful IOP Reduction Vs Cataract Surgery Alone
Glaukos Advances Eye Care Portfolio with Three-Year Epioxa Trial Data and Licensing Deal
Glaukos reports positive three-year Epioxa study results and secures an exclusive license for RevOpsis retinal candidate RO-104.